Loading…
The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model
IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission b...
Saved in:
Published in: | Frontiers in immunology 2023-08, Vol.14, p.1188392-1188392 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3 |
---|---|
cites | cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3 |
container_end_page | 1188392 |
container_issue | |
container_start_page | 1188392 |
container_title | Frontiers in immunology |
container_volume | 14 |
creator | Dickson, Alexandria Geerling, Elizabeth Stone, E. Taylor Hassert, Mariah Steffen, Tara L. Makkena, Taneesh Smither, Madeleine Schwetye, Katherine E. Zhang, Jianfeng Georges, Bertrand Roberts, M. Scot Suschak, John J. Pinto, Amelia K. Brien, James D. |
description | IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission. |
doi_str_mv | 10.3389/fimmu.2023.1188392 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5</doaj_id><sourcerecordid>2860619144</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</originalsourceid><addsrcrecordid>eNpVksFuEzEQhlcIJKrSF-DkI4du6rW9TnxCUVSgohISLVytWXu2cbW7DrY3Fa_DkzJpIkR9sT3zzzfSr7-q3jd8IeXKXPVhHOeF4EIumma1kka8qs4arVUthVCv_3u_rS5yfuR0lJFStmfVn_stshQHZLFne3AuTFBCnKg2F2RPoWwZTAw8TnEf0pzrPboSE_qTGlmY2C7FQmWau2SkgoG5OBXCXtKwZyXBlMeQ8wFM8kI779bf7-pN_FmLq6_Nqt6uN9eCjXHOB2B_hNHf4_CuetPDkPHidJ9XPz5d32--1LffPt9s1re1U0qXGgB1b-TSYNcrxzsBxktYOgNKtA4V9aVWqJWHXrcOPF-C4oZDBx1Z5uV5dXPk-giPdpfCCOm3jRDscyGmBwupBDegXXpOFNci771CgkmjW8VVq7n2HltifTyydnM3ondIbsDwAvqyM4WtfYh723CljVScCB9OhBR_zZiLJQMdDgNMSC5ZsaJdjWmUIqk4Sl2KOSfs_-1puD0kxD4nxB4SYk8JkX8BFDy0Gg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2860619144</pqid></control><display><type>article</type><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><source>PubMed Central</source><creator>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</creator><creatorcontrib>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</creatorcontrib><description>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2023.1188392</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>Immunology ; intramuscular vaccination ; intranasal vaccination ; SARS-CoV-2 ; vaccine efficacy ; vaccine immunogenicity ; virus transmission</subject><ispartof>Frontiers in immunology, 2023-08, Vol.14, p.1188392-1188392</ispartof><rights>Copyright © 2023 Dickson, Geerling, Stone, Hassert, Steffen, Makkena, Smither, Schwetye, Zhang, Georges, Roberts, Suschak, Pinto and Brien 2023 Dickson, Geerling, Stone, Hassert, Steffen, Makkena, Smither, Schwetye, Zhang, Georges, Roberts, Suschak, Pinto and Brien</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</citedby><cites>FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469340/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469340/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Dickson, Alexandria</creatorcontrib><creatorcontrib>Geerling, Elizabeth</creatorcontrib><creatorcontrib>Stone, E. Taylor</creatorcontrib><creatorcontrib>Hassert, Mariah</creatorcontrib><creatorcontrib>Steffen, Tara L.</creatorcontrib><creatorcontrib>Makkena, Taneesh</creatorcontrib><creatorcontrib>Smither, Madeleine</creatorcontrib><creatorcontrib>Schwetye, Katherine E.</creatorcontrib><creatorcontrib>Zhang, Jianfeng</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Roberts, M. Scot</creatorcontrib><creatorcontrib>Suschak, John J.</creatorcontrib><creatorcontrib>Pinto, Amelia K.</creatorcontrib><creatorcontrib>Brien, James D.</creatorcontrib><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><title>Frontiers in immunology</title><description>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</description><subject>Immunology</subject><subject>intramuscular vaccination</subject><subject>intranasal vaccination</subject><subject>SARS-CoV-2</subject><subject>vaccine efficacy</subject><subject>vaccine immunogenicity</subject><subject>virus transmission</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVksFuEzEQhlcIJKrSF-DkI4du6rW9TnxCUVSgohISLVytWXu2cbW7DrY3Fa_DkzJpIkR9sT3zzzfSr7-q3jd8IeXKXPVhHOeF4EIumma1kka8qs4arVUthVCv_3u_rS5yfuR0lJFStmfVn_stshQHZLFne3AuTFBCnKg2F2RPoWwZTAw8TnEf0pzrPboSE_qTGlmY2C7FQmWau2SkgoG5OBXCXtKwZyXBlMeQ8wFM8kI779bf7-pN_FmLq6_Nqt6uN9eCjXHOB2B_hNHf4_CuetPDkPHidJ9XPz5d32--1LffPt9s1re1U0qXGgB1b-TSYNcrxzsBxktYOgNKtA4V9aVWqJWHXrcOPF-C4oZDBx1Z5uV5dXPk-giPdpfCCOm3jRDscyGmBwupBDegXXpOFNci771CgkmjW8VVq7n2HltifTyydnM3ondIbsDwAvqyM4WtfYh723CljVScCB9OhBR_zZiLJQMdDgNMSC5ZsaJdjWmUIqk4Sl2KOSfs_-1puD0kxD4nxB4SYk8JkX8BFDy0Gg</recordid><startdate>20230816</startdate><enddate>20230816</enddate><creator>Dickson, Alexandria</creator><creator>Geerling, Elizabeth</creator><creator>Stone, E. Taylor</creator><creator>Hassert, Mariah</creator><creator>Steffen, Tara L.</creator><creator>Makkena, Taneesh</creator><creator>Smither, Madeleine</creator><creator>Schwetye, Katherine E.</creator><creator>Zhang, Jianfeng</creator><creator>Georges, Bertrand</creator><creator>Roberts, M. Scot</creator><creator>Suschak, John J.</creator><creator>Pinto, Amelia K.</creator><creator>Brien, James D.</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230816</creationdate><title>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</title><author>Dickson, Alexandria ; Geerling, Elizabeth ; Stone, E. Taylor ; Hassert, Mariah ; Steffen, Tara L. ; Makkena, Taneesh ; Smither, Madeleine ; Schwetye, Katherine E. ; Zhang, Jianfeng ; Georges, Bertrand ; Roberts, M. Scot ; Suschak, John J. ; Pinto, Amelia K. ; Brien, James D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Immunology</topic><topic>intramuscular vaccination</topic><topic>intranasal vaccination</topic><topic>SARS-CoV-2</topic><topic>vaccine efficacy</topic><topic>vaccine immunogenicity</topic><topic>virus transmission</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dickson, Alexandria</creatorcontrib><creatorcontrib>Geerling, Elizabeth</creatorcontrib><creatorcontrib>Stone, E. Taylor</creatorcontrib><creatorcontrib>Hassert, Mariah</creatorcontrib><creatorcontrib>Steffen, Tara L.</creatorcontrib><creatorcontrib>Makkena, Taneesh</creatorcontrib><creatorcontrib>Smither, Madeleine</creatorcontrib><creatorcontrib>Schwetye, Katherine E.</creatorcontrib><creatorcontrib>Zhang, Jianfeng</creatorcontrib><creatorcontrib>Georges, Bertrand</creatorcontrib><creatorcontrib>Roberts, M. Scot</creatorcontrib><creatorcontrib>Suschak, John J.</creatorcontrib><creatorcontrib>Pinto, Amelia K.</creatorcontrib><creatorcontrib>Brien, James D.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dickson, Alexandria</au><au>Geerling, Elizabeth</au><au>Stone, E. Taylor</au><au>Hassert, Mariah</au><au>Steffen, Tara L.</au><au>Makkena, Taneesh</au><au>Smither, Madeleine</au><au>Schwetye, Katherine E.</au><au>Zhang, Jianfeng</au><au>Georges, Bertrand</au><au>Roberts, M. Scot</au><au>Suschak, John J.</au><au>Pinto, Amelia K.</au><au>Brien, James D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model</atitle><jtitle>Frontiers in immunology</jtitle><date>2023-08-16</date><risdate>2023</risdate><volume>14</volume><spage>1188392</spage><epage>1188392</epage><pages>1188392-1188392</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>IntroductionVaccination is the most effective mechanism to prevent severe COVID-19. However, breakthrough infections and subsequent transmission of SARS-CoV-2 remain a significant problem. Intranasal vaccination has the potential to be more effective in preventing disease and limiting transmission between individuals as it induces potent responses at mucosal sites. MethodsUtilizing a replication-deficient adenovirus serotype 5-vectored vaccine expressing the SARS-CoV-2 RBD (AdCOVID) in homozygous and heterozygous transgenic K18-hACE2, we investigated the impact of the route of administration on vaccine immunogenicity, SARS-CoV-2 transmission, and survival. ResultsMice vaccinated with AdCOVID via the intramuscular or intranasal route and subsequently challenged with SARS-CoV-2 showed that animals vaccinated intranasally had improved cellular and mucosal antibody responses. Additionally, intranasally vaccinated animals had significantly better viremic control, and protection from lethal infection compared to intramuscularly vaccinated animals. Notably, in a novel transmission model, intranasal vaccination reduced viral transmission to naïve co-housed mice compared to intramuscular vaccination. DiscussionOur data provide convincing evidence for the use of intranasal vaccination in protecting against SARS-CoV-2 infection and transmission.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/fimmu.2023.1188392</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3224 |
ispartof | Frontiers in immunology, 2023-08, Vol.14, p.1188392-1188392 |
issn | 1664-3224 1664-3224 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7d0dafc5e0fd4e5ca39654045606dde5 |
source | PubMed Central |
subjects | Immunology intramuscular vaccination intranasal vaccination SARS-CoV-2 vaccine efficacy vaccine immunogenicity virus transmission |
title | The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T04%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20vaccination%20route%20with%20an%20adenovirus-vectored%20vaccine%20in%20protection,%20viral%20control,%20and%20transmission%20in%20the%20SARS-CoV-2/K18-hACE2%20mouse%20infection%20model&rft.jtitle=Frontiers%20in%20immunology&rft.au=Dickson,%20Alexandria&rft.date=2023-08-16&rft.volume=14&rft.spage=1188392&rft.epage=1188392&rft.pages=1188392-1188392&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2023.1188392&rft_dat=%3Cproquest_doaj_%3E2860619144%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-aae6f9379ebf4c0b2a9d3a7c9a425ce4aae364e64daf65cad07a4090abab392d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2860619144&rft_id=info:pmid/&rfr_iscdi=true |